Opus Genetics, Inc.
IRDCIK 0001228627 · Pharmaceutical Preparations · Nasdaq
- Ocuphire Pharma, Inc. (until 2024-10-22)
- REXAHN PHARMACEUTICALS, INC. (until 2020-11-09)
- CORPORATE ROAD SHOW DOT COM INC (until 2005-04-29)
- FERRARO FRANK (until 2003-04-29)
Revenue (TTM)
$12.49M
+29.1% YoY
Q1 May 2026
Net Income (TTM)
−$98.6M
+13.8% YoY
Q1 May 2026
EPS Diluted (TTM)
−$1.36
+62.8% YoY
Q1 May 2026
Gross Margin
99.2%
Q1 May 2026
Operating Margin
-332.4%
Q1 May 2026
Net Margin
-789.6%
Q1 May 2026
Free Cash Flow (TTM)
−$31.08M
Q1 May 2026
Cash
$59.96M
Q1 May 2026
Total Debt
$1.2M
Q1 May 2026
Shares Outstanding
81.4M sh
Q1 May 2026